For many young scientists, a PhD is the start of an international career.The next steps are often predictable: a prestigious research fellowship, a postdoctoral position abroad, publication in a leading journal, and eventually a faculty position.Dr. Parul Ganju There are those opportunities.She received her PhD in Skin Biology from the National Institute of Immunology (NII), New Delhi. She can receive a government research scholarship. Postdoctoral positions in the United States are also being considered.But something happened during her doctoral studies that changed her definition of success.She began meeting people with vitiligo, a chronic autoimmune disease in which the body’s immune system destroys pigment-producing cells, leaving white patches on the skin. In India, where appearance often affects self-confidence, relationships and even career opportunities, she realized the disease affected far more than just the skin.
Why Dr. Parul Ganju turned down the opportunity to seek treatment for vitiligo in the United States. (Photo: LinkedIn)
“The impact of this disease was enormous,” she later recalled. “People are waiting for something to work.”This question continued to plague her long after her Ph.D.Instead of asking where her career would take her, she started asking other questions.Who is actually developing treatments?
When a patient changed a scientist’s career direction
Dr. Ganju has spent several years studying skin biology, but interacting with patients has given her research new purpose.She realized that despite decades of scientific progress, treatment options for vitiligo were still limited.Commonly prescribed drugs, especially steroids, often broadly suppress the body’s immune system to slow down the disease. While they can help some patients, they do not permanently stop the disease, in many cases do not restore lost pigmentation, and long-term use may cause significant side effects.For the millions of people with vitiligo, there are still no treatments that directly target the root cause of the disease.Instead of accepting this reality, she decided to work hard to change it.
She gave up a comfortable career to launch a biotech startup
Dr. Parul Ganju co-founded Ahammune Biosciences in Pune in 2016 with her PhD collaborator Dr. Krishnamurthy Natarajan, professor at Jawaharlal Nehru University (JNU).This is an unconventional decision.Building a biotech company means years of uncertainty, financing, failed experiments and long clinical trials.But she believes publishing another research paper won’t immediately improve patients’ lives.Developing a drug might.The company’s lead drug candidate, AB1001, is designed to be different from existing treatments.Rather than broadly suppressing the body’s immune system, it is designed to block specific cell signaling pathways responsible for destroying melanocytes (the pigment-producing cells affected in vitiligo).Dr. Ganju describes this approach simply as “adding fuel to the fire.”Today, AB1001 has successfully completed Phase 1 clinical trials and has entered Phase 2 clinical trials, making it one step closer to becoming a new treatment option.The company has also secured patents in multiple countries and raised approximately $8 million in funding from investors including pi Ventures, Ideaspring Capital and Kotak Alternate Assets.
Why her story matters world allergy day
Today, July 8th, is seen globally as world allergy daya reminder of the growing impact of immune-related diseases and the importance of advancing research into immune system-driven diseases.Although vitiligo is not an allergy, it is an autoimmune disease in which the immune system mistakenly attacks healthy cells in the body.This commemoration provides an opportunity to appreciate the scientists who are working to better understand immune diseases and develop targeted therapies that improve the lives of patients.It also aligns with the wider message being conveyed through initiatives such as: national skin care day — Healthy skin is about more than just appearance. It’s about confidence, happiness and quality of life.
Sometimes the biggest career decisions aren’t about where you go, but why you stay
For students, Dr. Parul Ganju’s journey offers a different way of thinking about success.Many graduates dream of overseas research positions, prestigious scholarships and international careers.There is nothing wrong with these ambitions.But her story shows that sometimes the greatest impact comes from choosing a harder path—one driven by purpose rather than prestige.Millions of people around the world still suffer from vitiligo, and India has one of the highest numbers of vitiligo patients.Whether AB1001 ultimately becomes a widely used treatment will depend on the results of ongoing clinical trials and regulatory approval.But one thing is clear.A scientist who could have spent his career publishing papers instead chose to spend it solving a problem that patients have been facing for decades.Sometimes this kind of research is life-changing.Disclaimer: This article is based on publicly available information about Ahammune Biosciences’ Dr. Parul Ganju and the company’s ongoing clinical studies. References to AB1001 relate to its current stage of clinical development. The drug is still under investigation and has not yet received regulatory approval for general clinical use. This article is for informational and educational purposes only and should not be construed as medical advice.
